Colostral Proline-Rich Polypeptide Complexes. Comparative Study of the Antioxidant Properties, Cytokine-Inducing Activity, and Nitric Oxide Release of Preparations Produced by a Laboratory and a Large-Scale Method

Agnieszka Zabłocka,Małgorzata Mitkiewicz,Maria Janusz,Józefa Macała,Tadeusz Wilusz,Antoni Polanowski,Agata Sokołowska,Magdalena Bartoszewska

doi:10.1007/s10989-019-09876-6

Abstract

Colostral proline-rich polypeptide complex (PRP) with immunoregulatory and procognitive activities shows beneficial effects in Alzheimer’s disease (AD). As the laboratory method of isolating PRP is expensive, laborious, and time consuming, a new large-scale methanol method of PRP isolation was developed. The proline-rich polypeptide complex obtained by this new method (named methanol PRP–MPRP) from both ovine or bovine colostra shows psychotropic activity and inhibitory effect on amyloid β aggregation similar to those produced by the laboratory-scale method. The comparative study of the antioxidant properties, cytokine-inducing activity, and nitric oxide release of PRP and MPRP showed that preparations are biologically active, moreover MPRP should be used at concentration higher than 100 µg/ml to obtain results comparable to PRP.

Highlights

It was previously shown that proline-rich polypeptides (PRP) obtained from ovine colostrum by Janusz method and MPRP, obtained by Kruzel’s methanol method, as well as one of its peptide components (NP) inhibit Aβ aggregation, affect long-term memory, and increase neurite outgrowth (Popik et al 1999, 2001; Basci et al 2005; Schuster et al 2005; Janusz et al 2009)
With regard to IL-10 and TNF-α, MPRP showed an inducing activity only when as much as 100 μg of the preparation was used in the test, and that was equivalent to the effect of 5 μg of PRP (Fig. 1c, d)
It is suggested that both their antioxidant activity and their influence on cytokine and NO levels are rather connected with the lower-molecular-weight components of PRP complex

Summary

Introduction

Very substantial progress in elucidating the molecular mechanisms of the pathogenesis of neurodegenerative disorders allowed considering a new group of compounds with therapeutic significance as promising agents for modulation of the growth and function of central nervous system (CNS) cells (Barger et al 1995; Vitkovic et al 2000, 2001; Maccioni et al 2001; Mattson 2004; Parihar and Hemnani 2004; Steinman 2008; Lynch 2014; Weiner et al 2017). A complex of proline-rich polypeptides (PRP) was discovered and first isolated from ovine colostrum by Janusz et al (1974). The potential value of the proline-rich polypeptide complex in the treatment of AD was shown for the first time in a. International Journal of Peptide Research and Therapeutics (2020) 26:685–694 double-blinded placebo-controlled trial and a long-term open-label study (Leszek et al 1999, 2002) and confirmed in multicenter clinical trials (Bilikiewicz and Gaus 2004)

Methods

Results

Conclusion